Diagnostic aPpRoaches In Severe pneuMonia - the D-PRISM survey study

Definitions

For the purposes of this survey the following definitions will be used:

- 1. Community acquired Pneumonia (CAP): Pneumonia or suspected pneumonia present at hospital admission or manifesting within 48 hours of hospital admission.
- 2. Hospital Acquired Pneumonia (HAP): Pneumonia or suspected pneumonia not present at hospital admission and developing at least 48 hours after hospital admission (includes Non-ventilated ICU patients)
- 3. Ventilator Associated Pneumonia (VAP): Pneumonia or suspected pneumonia not present at ICU admission and developing at least 48 hours after initiation of mechanical ventilation (includes patients within 48 hours of extubation).

1. Specialty (please indicate all certified or training in)
Intensivist
Respiratory Physician
Anaesthetist
Other (please specify)
2. Grade
Consultant/Specialist
Trainee/Resident
3. Postgraduate ICU experience (years)
< 5
5-10
→ >10
4. In what country do you world
4. In what country do you work?
5. Unit Type
General ICU (mixed medical and surgical)
Cardiac ICU
Neuro ICU
Surgical ICU
Medical ICU

6. Unit Setting
University/ Teaching Hospital
Community District Hospital
Remote and rural hospital
7. Total number of beds in hospital
8. Total number of beds in unit
9. Routine management of hematological malignancy/bone marrow transplant/organ transplant (>5 patients from any of these groups/month)?
○ Yes
○ No
10. Do you have guidelines for antibiotic prescribing in severe pneumonia?
Yes
○ No
11. Do you have an antimicrobial stewardship programme/ agreed protocol for monitoring use of antibiotics/ involvement of microbiologists/infection diseases experts?
Yes
○ No
12. Do you have access to diagnostic bronchoscopy?
Yes
○ No
13. If yes to Q12, please state availability
24 hours, 7 days/week
Specific hours, every day
Specific weekdays only
14. Who provides diagnostic bronchoscopy?
☐ Intensivist
Pulmonologist from outside unit
Other (please specify)

_	_	ow would you classif	y your level of	training?
Formal trainin				
Informal traini	ing			
One training				
		ou rate your level of olume (ml) you use fo		performing BAL?
18. What does your	lab report for each	n of the following mic	crobiological sa	amples?
	Quantitative/Semi- quantitative (Colony Forming Unit)	Qualitative (small, moderate, heavy growth)	Positive/ Negative	This technique is not used in my hospital
Sputum/ Endotracheal aspirates	0	0	\bigcirc	0
blind (non- bronchoscopic) mini- BAL	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Bronchoscopic BAL				
Blood Cultures	\bigcirc	\bigcirc		
Other body fluids (eg pleural fluid)	\circ	0		0
19. Do you use any see top of survey fo	or definitions of the		eumonia (CAP,F	
G: 1	Yes	No		Don't know
Streptococcal urinary antigen				
Legionella urinary antigen				\bigcirc
Single organism PCR - if yes, see Q22	\bigcirc	0		
Multiplex Respiratory pathogens- if yes, see Q23		\circ		\circ
20. If single organis	sm PCRs are used,	please specify the or	ganism(s) (lea	ve blank if not used)

not used)				ens (leave blank if	
Biofire Filmarray					
Curetis Unyvero					
Seegene Allplex					
Qiagen RespiFinder					
In-house lab develope	d test				
Multiplex used but un					
Other commercial ass					
Other commercial ass			\neg		
22. If there are barriers to the use of multiplex respiratory PCR assays in your hospital please list them here (e.g. cost, lack of expertise, difficulty obtaining reagents)?23. In Community Acquired Pneumonia (CAP), how frequently is each of the following diagnostic criteria assessed? Select the most appropriate response:					
	Always	Mostly	Sometimes	Never	
Clinical (positive findings on auscultation such as bronchi, crepitations, wheeze, breathlessness, purulent sputum, impaired oxygenation or ventilation)		0	0		
Radiological (CXR or CT showing lobar infiltration/bronchogram, diffuse/patchy shadowing)		\bigcirc	\circ	\circ	
Sonological (USS showing consolidation/bronchogram)	\circ		\bigcirc		
24. For each category of	diagnostic criteria in	CAP select	the most appropr	riate ontion	
- 1, 1 of odon odoogoty of	_	0711 , 501000		nate option.	
	Some or all must be present for diagnosis	Supportive		t part of diagnostic assessment	
Clinical (positive findings on auscultation such as bronchi, crepitations, wheeze, breathlessness, purulent sputum, impaired oxygenation or ventilation)		Supportive	for diagnosis No	t part of diagnostic	
Clinical (positive findings on auscultation such as bronchi, crepitations, wheeze, breathlessness, purulent sputum, impaired		Supportive	for diagnosis No	t part of diagnostic	

	Always	Mostly	Sometimes	Never
putum/Endotracheal pirate	\bigcirc			
slind Mini-BAL ventilated patients nly)			\bigcirc	
Bronchoscopic BAL ventilated patient)	\bigcirc			
Bronchoscopic BAL spontaneously oreathing patient)	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Blood cultures				
Other body fluids (eg leural fluid)	\bigcirc	\bigcirc	\circ	\bigcirc
Dual therapy includ Dual therapy includ				
27. State the intende 4 days 5-7 days 8-12 days >12 days Other (please specif	d duration of the	erapy in CAP if pa		
27. State the intende 4 days 5-7 days 8-12 days >12 days	d duration of the	erapy in CAP if pa	ently is each of the	
27. State the intende 4 days 5-7 days 8-12 days >12 days Other (please specif	d duration of the	erapy in CAP if pa	ently is each of the	
27. State the intende 4 days 5-7 days 8-12 days >12 days Other (please specifications) B. In Hospital-acquiragnostic criteria assessing a continuous	d duration of the	(HAP), how frequences appropriate	ently is each of the response:	following
27. State the intende 4 days 5-7 days 8-12 days >12 days Other (please specif	d duration of the	(HAP), how frequences appropriate	ently is each of the response:	following

showing lobar infiltration/bronchogram, diffuse/patchy shadowing) Sonological (USS showing consolidation/bronchogram) O. Regarding the microbiological diagnosis of pneumonia HAP, how often do you assess each fithe following? Always Mostly Sometimes Never Sputum/Endotracheal aspirate Blind mini-BAL (ventilated patients only) Bronchoscopic BAL (ventilated patients) Bronchoscopic BAL (spontaneously breathing patients) Blood cultures Other body fluids (eg	3. For each category of	i diagnostic criteria i	n HAP , select the most a	appropriate option.
mausculation such as promochi, crepitations, wheeze, breathlessness, purulent sputum, impaired systems, in a second state of the following of the following of the following of the following? Always Mostly Sometimes Never Sputum/Endotracheal spirate Always Mostly Sometimes Never Sputum/Endotracheal spirate Bilind min-BAL systems of the following of t				-
showing lobar infiltration/bronchogram, diffuse/patchy shadowing) Sonological (USS showing consolidation/bronchogram) O. Regarding the microbiological diagnosis of pneumonia HAP, how often do you assess eac f the following? Always Mostly Sometimes Never Sputum/Endotracheal aspirate Always Mostly Sometimes Over Sputum/Endotracheal aspirate Blind mini-BAL (ventilated patients only) Bronchoscopic BAL (ventilated patients) Bronchoscopic BAL (ventilated patients) Bronchoscopic BAL (spontaneously breathing patients) Blood cultures Other body fluids (eg pleural fluid) 31. What is your initial antibiotic regime for HAP? Monotherapy for all patients Dual therapy including coverage for resistant organisms (eg MRSA/MDR Pseudomonas) for all patients Monotherapy for low risk of resistant organisms, dual therapy for high risk of resistant organisms (eg MRSA/MDR pseudomonas) 32. State the intended duration of therapy in HAP if patient reponds to initial treatment: 4 days 5-7 days 8-12 days > 12 days	on auscultation such as bronchi, crepitations, wheeze, breathlessness, purulent sputum, impaired	0		0
Always Mostly Sometimes Never Sputum/Endotracheal aspirate	Radiological (CXR or CT showing lobar infiltration/bronchogram, diffuse/patchy shadowing)	\bigcirc		
Sputum/Endotracheal aspirate Blind mini-BAL (ventilated patients only) Bronchoscopic BAL (ventilated patients) Bronchoscopic BAL (spontaneously breathing patients) Bronchoscopic BAL (spontaneously breathing patients) Blood cultures Other body fluids (eg pleural fluid) 31. What is your initial antibiotic regime for HAP? Monotherapy for all patients Dual therapy including coverage for resistant organisms (eg MRSA/MDR Pseudomonas) for all patients Monotherapy for low risk of resistant organisms, dual therapy for high risk of resistant organisms (eg MRSA/MDR pseudomonas) 32. State the intended duration of therapy in HAP if patient reponds to initial treatment: 4 days 5-7 days 8-12 days >>12 days)	\bigcirc	\circ
Sputum/Endotracheal aspirate Blind mini-BAL (ventilated patients only) Bronchoscopic BAL (ventilated patients) Bronchoscopic BAL (spontaneously breathing patients) Bronchoscopic BAL (spontaneously breathing patients) Blood cultures Other body fluids (eg pleural fluid) 31. What is your initial antibiotic regime for HAP? Monotherapy for all patients Dual therapy including coverage for resistant organisms (eg MRSA/MDR Pseudomonas) for all patients Monotherapy for low risk of resistant organisms, dual therapy for high risk of resistant organisms (eg MRSA/MDR pseudomonas) 32. State the intended duration of therapy in HAP if patient reponds to initial treatment: 4 days 5-7 days 8-12 days >>12 days		obiological diagnosis	of pneumonia HAP, how o	often do you assess each
aspirate Blind mini-BAL (ventilated patients only) Bronchoscopic BAL (spontaneously breathing patients) Blood cultures Other body fluids (eg pleural fluid) 31. What is your initial antibiotic regime for HAP? Monotherapy for all patients Dual therapy including coverage for resistant organisms (eg MRSA/MDR Pseudomonas) for all patients Monotherapy for low risk of resistant organisms, dual therapy for high risk of resistant organisms (eg MRSA/MDR pseudomonas) 32. State the intended duration of therapy in HAP if patient reponds to initial treatment: 4 days 5-7 days 8-12 days >12 days		Always	Mostly Sometime	s Never
(ventilated patients only) Bronchoscopic BAL (ventilated patients) Bronchoscopic BAL (spontaneously breathing patients) Blood cultures Other body fluids (eg pleural fluid) 31. What is your initial antibiotic regime for HAP? Monotherapy for all patients Dual therapy including coverage for resistant organisms (eg MRSA/MDR Pseudomonas) for all patients Monotherapy for low risk of resistant organisms, dual therapy for high risk of resistant organisms (eg MRSA/MDR pseudomonas) 32. State the intended duration of therapy in HAP if patient reponds to initial treatment: 4 days 5-7 days 8-12 days >12 days			\circ	\circ
(spontaneously breathing patients) Blood cultures Other body fluids (eg pleural fluid) 31. What is your initial antibiotic regime for HAP? Monotherapy for all patients Dual therapy including coverage for resistant organisms (eg MRSA/MDR Pseudomonas) for all patients Monotherapy for low risk of resistant organisms, dual therapy for high risk of resistant organisms (eg MRSA/MDR pseudomonas) 32. State the intended duration of therapy in HAP if patient reponds to initial treatment: 4 days 5-7 days 8-12 days >12 days	(ventilated patients	\bigcirc	\circ	\bigcirc
Monotherapy for all patients Dual therapy including coverage for resistant organisms (eg MRSA/MDR Pseudomonas) for all patients Monotherapy for low risk of resistant organisms, dual therapy for high risk of resistant organisms (eg MRSA/MDR pseudomonas) 32. State the intended duration of therapy in HAP if patient reponds to initial treatment: 4 days 5-7 days 8-12 days >12 days			\circ	
Other body fluids (eg pleural fluid) 31. What is your initial antibiotic regime for HAP? Monotherapy for all patients Dual therapy including coverage for resistant organisms (eg MRSA/MDR Pseudomonas) for all patients Monotherapy for low risk of resistant organisms, dual therapy for high risk of resistant organisms (eg MRSA/MDR pseudomonas) 32. State the intended duration of therapy in HAP if patient reponds to initial treatment: 4 days 5-7 days 8-12 days >12 days	(spontaneously	\circ	0 0	\circ
31. What is your initial antibiotic regime for HAP? Monotherapy for all patients Dual therapy including coverage for resistant organisms (eg MRSA/MDR Pseudomonas) for all patients Monotherapy for low risk of resistant organisms, dual therapy for high risk of resistant organisms (eg MRSA/MDR pseudomonas) 32. State the intended duration of therapy in HAP if patient reponds to initial treatment: 4 days 5-7 days 8-12 days >12 days	Blood cultures		\circ	
 Monotherapy for all patients Dual therapy including coverage for resistant organisms (eg MRSA/MDR Pseudomonas) for all patients Monotherapy for low risk of resistant organisms, dual therapy for high risk of resistant organisms (eg MRSA/MDR pseudomonas) 32. State the intended duration of therapy in HAP if patient reponds to initial treatment: 4 days 5-7 days 8-12 days >12 days 		\bigcirc	0 0	\bigcirc
Dual therapy including coverage for resistant organisms (eg MRSA/MDR Pseudomonas) for all patients Monotherapy for low risk of resistant organisms, dual therapy for high risk of resistant organisms (eg MRSA/MDR pseudomonas) 32. State the intended duration of therapy in HAP if patient reponds to initial treatment: 4 days 5-7 days 8-12 days >12 days	31. What is your initi	al antibiotic regime f	for HAP ?	
Monotherapy for low risk of resistant organisms, dual therapy for high risk of resistant organisms (eg MRSA/MDR pseudomonas) 32. State the intended duration of therapy in HAP if patient reponds to initial treatment: 4 days 5-7 days 8-12 days >12 days	Monotherapy for all	patients		
MRSA/MDR pseudomonas) 32. State the intended duration of therapy in HAP if patient reponds to initial treatment: 4 days 5-7 days 8-12 days >12 days	Oual therapy includ	ing coverage for resistant	organisms (eg MRSA/MDR Pse	eudomonas) for all patients
4 days 5-7 days 8-12 days >12 days			ms, dual therapy for high risk o	of resistant organisms (eg
4 days 5-7 days 8-12 days >12 days	32 State the intende	d duration of theres	, in HAD if patient range	de to initial treatment.
5-7 days 8-12 days >12 days		a auradon or merapy	m im n panent repond	13 10 mmai tredillelli:
8-12 days >12 days				
>12 days				
		C)		

33. Do you use an 'anti	biotic time out' to re	eview continu	uing antibiotics at	48-72 hours in
Yes				
○ No				
34. In VAP , how frequent most appropriate respons	e:			
Clinical (positive findings	Always	Mostly	Sometimes	Never
on auscultation such as bronchi, crepitations, wheeze, breathlessness, purulent sputum, impaired oxygenation or ventilation)		0	0	0
Radiological (CXR or CT showing lobar infiltration/bronchogram, diffuse/patchy shadowing)	\circ	\bigcirc	\circ	\circ
Sonological (USS showing consolidation/bronchogram)				
Clinical (positive findings on auscultation such as bronchi, crepitations, wheeze, breathlessness, purulent sputum, impaired oxygenation or ventilation)		(0	0
oxygenation or ventilation) Radiological (CXR or CT showing lobar infiltration/bronchogram,		(\circ	0
diffuse/patchy shadowing) Sonological (USS showing consolidation/bronchogram)		(\bigcirc	0
36. Regarding the microbof the following?	iological diagnosis (of pneumonia	VAP , how often d	lo you assess eacl
	Always	Mostly	Sometimes	Never
Sputum/Endotracheal aspirate	\bigcirc		\bigcirc	
Blind mini-BAL	\bigcirc	\bigcirc		
Bronchoscopic BAL				
Blood cultures		\bigcirc		
Other body fluids (e.g. pleural fluid)		\bigcirc		

37. What is your initial antibiotic regime for VAP ?	
Monotherapy for all patients	
Oual therapy including coverage for resistant organisms (eg MRSA/MDR Pseudon	nonas) for all patients
 Monotherapy for low risk of resistant organisms, dual therapy for high risk of resistant organisms, dual therapy for high risk of resistant organisms. 	istant organisms (eg
38. State the intended duration of therapy in VAP if patient responds to	initial treatment:
4 days	
5-7 days	
8-12 days	
>12 days	
Other (please specify):	
39. Do you use an 'antibiotic time out' to review continuing antibiotics a	at 48-72 hours in VAP
Yes	
○ No	